Eli Lilly has escalated its campaign against the illicit market for its investigational obesity drug retatrutide, filing six lawsuits on August 12 against U.S. entities it accuses of selling black-market versions of the medicine — which remains unapproved by any regulator in the world (Lilly press release).
The lawsuits target a mix of compounding pharmacies, medical spas, and online sellers: Aesthetic Envy Cosmetic Centers (California), and five Texas companies — Astra LLC (d/b/a Astra Peptides), Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co. (Reuters). Four of the defendants advertise retatrutide “for research use only” without a prescription — products Lilly says are in fact intended for human injection (CBS News).
”What is being sold is not a medicine”
Lilly’s chief medical officer, David A. Hyman, framed the action as patient protection: “What is being sold on the black market is not a medicine — it is entirely unverified, unapproved and not worth the risk.” The company notes the FDA has already made clear that sales of unapproved retatrutide to consumers are illegal, that retatrutide cannot lawfully be compounded, and that “research-use only” products “are of unknown quality and may be harmful.”
Beyond the six lawsuits, Lilly said it has referred more than 200 individuals and entities to the FDA, the U.S. Department of Justice, state attorneys general, and professional licensing boards, and has reported more than 14,000 websites, advertisements, social media posts, and product listings unlawfully marketing retatrutide in over 100 countries to internet service providers, social media platforms, and e-commerce companies (press release).
The company is also calling on social media and e-commerce platforms, credit card companies, payment processors, and shipping carriers to cut off the infrastructure enabling the trade. “Six lawsuits is not going to be the solution to everything, but it is a start,” Max Denning, an associate vice president at Lilly, told CBS News.
The lawsuits’ allegations
Lilly alleges the defendants endanger consumers with substances that haven’t been vetted by regulators and are more likely to contain contaminants. In its complaint against Striker Pharmacy, the company writes that “consumers are switching from Lilly’s FDA-approved medicines to illegal retatrutide products, citing purported lower costs and perceived superior efficacy” — and warns that bad reactions to black-market products could “poison the well for the future of retatrutide medicines” (CBS News).
The suits are the latest in a series of legal actions Lilly has taken against copycat sellers. In 2023, the company sued eight companies in five states for producing or selling compounded versions of Mounjaro, and later filed against six more for false advertising (Fierce Pharma).
Canadian context
For Canadians, the enforcement action underscores a warning this site has repeated: no legitimate retatrutide product exists for sale anywhere in the world. The black market documented in the U.S. — peptide vendors, med spas, and even convenience stores — operates through channels that reach Canadian consumers too, and Health Canada has repeatedly warned about unapproved weight-loss products sold online, including peptides imported from unregulated foreign manufacturers.
Canadians who encounter retatrutide for sale — online, in clinics, or through social media — should treat it as unapproved and unverified, and can report suspicious products to Health Canada’s Health Product Complaint and Incident Reporting system. The only legitimate ways to access retatrutide in Canada remain participation in a clinical trial or a case-by-case Special Access Programme request.
Retatrutide remains an investigational drug not approved by Health Canada, the FDA, or any other regulator. No medicine containing retatrutide can lawfully be sold to consumers.
Sources
- Eli Lilly press release: “Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market” — August 12, 2026
- Reuters: “Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide” — August 12, 2026
- CBS News: “Eli Lilly takes aim at illicit market for its experimental weight-loss drug” — August 12, 2026
- Fierce Pharma: “Lilly takes 6 companies to court for selling retatrutide knockoffs” — August 12, 2026
- BioPharma Dive: “Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide” — August 12, 2026
- FDA: “FDA’s concerns with unapproved GLP-1 drugs used for weight loss”